Imagion Biosystems Limited (ASX:IBXO)

Market Cap	8.62M
Revenue (ttm)	1.06M
Net Income (ttm)	-2.20M
Shares Out	n/a
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	300,000
Average Volume	3,806,126
Open	0.0110
Previous Close	0.0100
Day's Range	0.0110 - 0.0120
52-Week Range	0.0020 - 0.0220
Beta	n/a
RSI	53.16
Earnings Date	Nov 27, 2025

About Imagion Biosystems

Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It is involved in the nanotechnology; biotechnology; and cancer diagnostics businesses. The company develops MagSense, which completed Phase 1 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to detect cancer. The company has collaboration with Siemens MRI to support the Phase 2 study of MagSense HER2 imaging agent...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 2016
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IBXO